Pain Therapeutics (NASDAQ:PTIE) Lowered to Strong Sell at ValuEngine

Pain Therapeutics (NASDAQ:PTIE) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Friday, December 1st.

Separately, Zacks Investment Research downgraded Pain Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, September 19th.

Pain Therapeutics (PTIE) opened at $4.17 on Friday. Pain Therapeutics has a 52 week low of $3.10 and a 52 week high of $9.31.

Pain Therapeutics (NASDAQ:PTIE) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.40) earnings per share for the quarter. equities research analysts anticipate that Pain Therapeutics will post -2.2 earnings per share for the current year.

A hedge fund recently bought a new stake in Pain Therapeutics stock. Dimensional Fund Advisors LP bought a new position in shares of Pain Therapeutics, Inc. (NASDAQ:PTIE) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 59,989 shares of the biopharmaceutical company’s stock, valued at approximately $247,000. Dimensional Fund Advisors LP owned approximately 0.91% of Pain Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 36.16% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Pain Therapeutics (NASDAQ:PTIE) Lowered to Strong Sell at ValuEngine” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at

About Pain Therapeutics

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Pain Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply